Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ezetimibe

FDA-approved product (tablet, oral), marketed as Ezetimibe, Zetia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ezetimibe
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Familial hypercholesterolemia
  • Homozygous familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other lipid modifying agents
FDA pharmacologic class
Dietary Cholesterol Absorption Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ezetimibe in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ezetimibe with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

    NCT00110435 · start 2005-05

    Registered record
    Registry ID
    NCT00110435
    Conditions
    Type 2 Diabetes Mellitus; Hypercholesterolemia
    Interventions
    MK0653A, ezetimibe (+) simvastatin; Duration of Treatment: 4 wk placebo run in then 6 wk active; Comparator: atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-05
    Completion
    2005-12
    Enrolment
    1,229

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Hypercholesterolemia
    InterventionMK0653A, ezetimibe (+) simvastatin; Duration of Treatment: 4 wk placebo run in then 6 wk active; Comparator: atorvastatin
    PhasePhase 3
    Registry statusCompleted

  • Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe

    NCT01424891 · start 2004-04

    Registered record
    Registry ID
    NCT01424891
    Conditions
    Type 2 Diabetes; Inflammation
    Interventions
    Simvastatin 80 mg; Sim10/Eze10; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-04
    Completion
    2011-08
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Inflammation
    InterventionSimvastatin 80 mg; Sim10/Eze10; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)

    NCT00092586 · start 2002-09

    Registered record
    Registry ID
    NCT00092586
    Conditions
    Hypercholesterolemia
    Interventions
    MK0653, ezetimibe; Comparator: statins
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-09
    Completion
    2003-10
    Enrolment
    2,904

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionMK0653, ezetimibe; Comparator: statins
    PhasePhase 3
    Registry statusCompleted

  • Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)

    NCT00092833 · start 2002-07

    Registered record
    Registry ID
    NCT00092833
    Conditions
    Hypercholesterolemia, Familial; Lipid Metabolism, Inborn Errors
    Interventions
    Comparator: ezetimibe
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2002-07
    Completion
    2005-05
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia, Familial; Lipid Metabolism, Inborn Errors
    InterventionComparator: ezetimibe
    PhasePhase 3
    Registry statusTerminated

  • Sitosterolemia Extension Study (0653-004)(COMPLETED)

    NCT00092820 · start 2001-02-12

    Registered record
    Registry ID
    NCT00092820
    Conditions
    Lipid Metabolism, Inborn Errors; Heart Disease
    Interventions
    MK0653, ezetimibe; Comparator: placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02-12
    Completion
    2004-11-30
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLipid Metabolism, Inborn Errors; Heart Disease
    InterventionMK0653, ezetimibe; Comparator: placebo
    PhasePhase 3
    Registry statusCompleted